Int'l Appl'n No.: PCT/GB03/01777

Case No.: T1576P

Amendments to the Claims:

Page No.: 3 10 / 511915 DT01 Rec'd PCT/PTC 18 OCT 2004

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1(Original) A compound of formula I:

$$CF_3$$
 $O > S - N$
 $*$
 $X-R$

wherein the moiety X-R is attached at one of the positions indicated by an asterisk; X is a 5-(R-substituted)-1,2,4-oxadiazol-3-yl moiety; and R is selected from:

- (i) a non-aromatic hydrocarbon group of up to 10 carbon atoms, optionally substituted with halogen, CF₃, CHF₂, CN, OH, CO₂H, C₂₋₆acyl, C₁₋₄alkoxy or C₁₋₄alkoxycarbonyl;
- (ii) a non-aromatic heterocyclic group comprising up to 7 ring atoms of which up to 3 are chosen from N, O and S and the remainder are carbon, bearing 0-3 substituents independently selected from oxo, halogen, CN, C₁₋₆alkyl, OH, CF₃, CHF₂, CH₂F, C₂₋₆acyl, CO₂H, C₁₋₄alkoxy and C₁₋₄alkoxycarbonyl; and
- (iii) phenyl or 6-membered heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CF₃, CHF₂, CH₂F, NO₂, CN, OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy; or a pharmaceutically acceptable salt thereof.

Claim 2 (Original) A compound according to claim 1 which is homochiral and is [6S,9R,11R]2',3',4',5,5',6,7,8,9,10-decahydro-2-(5-(R-substituted)-1,2,4-oxadiazol-3-yl)-5'-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide, or a pharmaceutically acceptable salt thereof.

Claim 3 (Original) A compound according to claim 1 or claim 2 wherein R represents phenyl or a 6-membered heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CF₃, CHF₂, CH₂F, NO₂, CN, OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy.

Int'l Appl'n No.: PCT/GB03/01777 Case No.: T1576P Page No.: 4

Claim 4 (Original) A compound according to claim 3 wherein R is selected from monohalophenyl, dihalophenyl, pyridyl, monohalopyridyl and trifluoromethylpyridyl, wherein

"halo" refers to fluoro or chloro.

A compound according to claim 1 or claim 2 wherein the moiety Claim 5 (Original)

-X-R is selected from:

Claim 6 (Amended) A pharmaceutical composition comprising a compound according to any previous claim 1 and a pharmaceutically acceptable carrier.

Claim 7-8 Cancelled

Claim 9 (Amended) A method of treatment of a subject suffering from or prone to Alzheimer's disease which comprises administering to that subject an effective amount of a compound according to claim 1 any of claims 1-5.